Search

Displaying results 4551 - 4560 of 8967 in total
  1. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and … NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a placebo).

  2. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). … It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors

  3. Drug

    Hydroxyethyl ethylcellulose

    go.drugbank.com/drugs/DB14139
    Approved

    Hydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    KAND567

    go.drugbank.com/drugs/DB16511
    Investigational

    KAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation[L32908]. … Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908].

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV). … C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment

  6. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    The bacille Calmette-Guérin (BCG) vaccine protects against severe extrapulmonary forms of tuberculosis (TB) but does not adequately protect against pulmonary TB -- the most prevalent form of TB. … The ability for mycobacterial antigens to reach the cytosol is due to this vaccine being engineered to secrete Hly which perforates phagosomal membranes.

  7. Drug

    Parachlorophenol

    go.drugbank.com/drugs/DB13154
    ApprovedWithdrawn

    Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.

  8. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244584] Etrolizumab is a humanized IgG1κ monoclonal antibody directed against the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins that, due to its target specificity, appears as or more … [A244564, A244569, A244574, A244584] Etrolizumab is currently under investigation for the treatment of ulcerative colitis and Crohn's disease.

  9. Drug

    LC16M8

    go.drugbank.com/drugs/DB05019
    Investigational

    It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection. … LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines.

  10. Drug

    VCA-894A

    go.drugbank.com/drugs/DB18609
    Investigational

    VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'